4.4 Article

Inflammatory Bowel Disease-Unclassified in Children: Diagnosis and Pharmacological Management

Journal

PEDIATRIC DRUGS
Volume 19, Issue 2, Pages 113-120

Publisher

ADIS INT LTD
DOI: 10.1007/s40272-017-0213-9

Keywords

-

Ask authors/readers for more resources

Inflammatory bowel diseases are chronic disorders of the gastrointestinal tract that include Crohn's disease (CD), ulcerative colitis (UC) and inflammatory bowel disease-unclassified (IBDU). The latter defines a subgroup of patients with clinical and endoscopic evidence of chronic colitis, without specific features of either CD or UC. These patients will possibly be re-classified as having UC or CD during the follow-up, although a significant percentage of them will keep the diagnosis of IBDU. IBDU is the rarest subtype of IBD, both in children and in adults, although it is twice as common among the pediatric population, especially in the younger ages. The diagnosis can only be made after a comprehensive diagnostic work-up, combining clinical history, physical and laboratory examination, upper and lower gastrointestinal endoscopy, with histology and imaging of the small bowel. The therapeutic strategy is borrowed from that of UC and CD, although recent data suggest that IBDU has a lower therapeutic burden with a generally mild disease course and a good response to mesalamine. Since there are only few published data on pediatric IBDU, and no guidelines on its management are available, this review aims at summarizing the most recent evidence for the diagnostic work-up with a specific focus on medical and surgical options in the treatment of IBDU.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Meeting Abstract Gastroenterology & Hepatology

TRENDS IN ADMISSIONS, OUTCOMES AND FINANCIAL BURDEN OF C. DIFFICILE INFECTION RELATED HOSPITALIZATIONS AMONG INFLAMMATORY BOWEL DISEASE PATIENTS: A NATIONWIDE ANALYSIS

Tal Berger, Huey Miin Lee, Lavenya Ramasamy Padmanaban, Eytan Wine, Anat Yerushalmy-Feler, Iva Hojsak, Denis Kazeka, Daniela Elena Serban, Dotan Yogev, Oren Ledder, Paolo Lionetti, Luca Scarallo, Marco Gasparetto, Nicholas M. Croft, Erasmo Miele, Annamaria Staiano, Joseph Meredith, Marina Aloi, Patrizia Alvisi, Darja Urlep, Batia Weiss, Mikkel Malham, Manar Matar, Victor Navas-Lopez, Claudio Romano, Valeria Dipasquale, Lorenzo Norsa, Kaija-Leena Kolho, Raanan Shamir, Dror Shouval

INFLAMMATORY BOWEL DISEASES (2022)

Article Gastroenterology & Hepatology

Clinical Features and Outcomes of Paediatric Patients With Isolated Colonic Crohn Disease

Tal David Berger, Huey Miin Lee, Lavenya Ramasamy Padmanaban, Eytan Wine, Anat Yerushalmy-Feler, Iva Hojsak, Denis Kazeka, Daniela Elena Serban, Dotan Yogev, Oren Ledder, Paolo Lionetti, Luca Scarallo, Marco Gasparetto, Nicholas M. Croft, Erasmo Miele, Annamaria Staiano, Joseph Meredith, Marina Aloi, Patrizia Alvisi, Darja Urlep, Batia Weiss, Mikkel Malham, Manar Matar, Victor Manuel Navas-Lopez, Claudio Romano, Valeria Dipasquale, Lorenzo Norsa, Kaija-Leena Kolho, Raanan Shamir, Dror S. Shouval

Summary: Significant differences are observed in the clinical presentation and outcomes of paediatric patients with L2, compared to patients with L1 and UC. L2 patients have lower rates of hematochezia and fever, skip lesions in the intestines, and lower antibody positivity. Response rates to exclusive enteral nutrition and oral steroids are comparable between L1 and L2 patients, but L1 patients are commenced on anti-TNF alpha earlier. Moreover, stricturing phenotype and need for colectomy are very rare in L2 patients.

JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2022)

Article Pediatrics

Real-Life Use of Biosimilars in Pediatric Inflammatory Bowel Disease: A Nation-Wide Web Survey on Behalf of the SIGENP IBD Working Group

Valeria Dipasquale, Massimo Martinelli, Marina Aloi, Salvatore Accomando, Patrizia Alvisi, Serena Arrigo, Claudia Banzato, Matteo Bramuzzo, Mara Cananzi, Mara Corpino, Clelia Di Mari, Giovanni Di Nardo, Anna Dilillo, Natale Dodaro, Enrico Felici, Simona Gatti, Francesco Graziano, Maria Teresa Illiceto, Lorenzo Norsa, Anna Opramolla, Maria Pastore, Paolo Maria Pavanello, Erminia Romeo, Luca Scarallo, Caterina Strisciuglio, Giovanna Zuin, Claudio Romano

Summary: The survey of members of the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition showed high awareness and utilization of biosimilars in treating inflammatory bowel disease. Participants acknowledged similar efficacy and safety of biosimilars compared to originator drugs, with cost-saving being the main advantage. The majority reported switching from originator to biosimilars in their clinical practice with no significant adverse events, indicating a favorable and confident stance towards biosimilar use in pediatric IBD.

PEDIATRIC DRUGS (2022)

Article Gastroenterology & Hepatology

Children included in randomised controlled trials of biologics in inflammatory bowel diseases do not represent the real-world patient-mix

Ohad Atia, Gemma Pujol-Muncunill, Victor Manuel Navas-Lopez, Esther Orlanski-Meyer, Oren Ledder, Raffi Lev-Tzion, Gili Focht, Eyal Shteyer, Ronen Stein, Marina Aloi, Richard K. Russell, Javier Martin-de-Carpi, Dan Turner

Summary: This study compared the treatment response to biologics in routine practice for children with inflammatory bowel diseases (IBD) who would and would not have been eligible for enrolment in the regulatory randomised controlled trials (RCTs) of the same drug. The results showed that most children initiating biologics for IBD in clinical practice would not have been eligible for the corresponding regulatory RCTs, and the outcomes of ineligible patients were worse than for eligible patients.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)

Article Gastroenterology & Hepatology

Occurrence and Clinical Impact of Eosinophilic Esophagitis in a Large Cohort of Children With Inflammatory Bowel Disease

Marina Aloi, Giulia D'Arcangelo, Danilo Rossetti, Simone Bucherini, Enrico Felici, Claudio Romano, Massimo Martinelli, Valeria Dipasquale, Paolo Lionetti, Salvatore Oliva

Summary: This study investigated the association between pediatric inflammatory bowel disease (IBD) and eosinophilic esophagitis (EoE). The results suggest that having EoE may be associated with a milder IBD disease course.

INFLAMMATORY BOWEL DISEASES (2023)

Article Gastroenterology & Hepatology

Induction of Remission With Exclusive Enteral Nutrition in Children With Crohn's Disease: Determinants of Higher Adherence and Response

Marialaura Cuomo, Alessandra Carobbio, Marina Aloi, Patrizia Alvisi, Claudia Banzato, Luca Bosa, Matteo Bramuzzo, Angelo Campanozzi, Giulia Catassi, Lorenzo D'Antiga, Monica Di Paola, Enrico Felici, Maria Teresa Fioretti, Simona Gatti, Francesco Graziano, Sara Lega, Paolo Lionetti, Antonio Marseglia, Massimo Martinelli, Francesca Musto, Naire Sansotta, Luca Scarallo, Giovanna Zuin, Lorenzo Norsa

Summary: Exclusive enteral nutrition is the first choice for inducing remission in pediatric Crohn's disease, but adherence to this treatment can be challenging for children. This study aimed to identify factors predictive of nonadherence and nonremission. The results showed that colonic involvement and high fecal calprotectin levels at diagnosis were associated with reduced adherence to exclusive enteral nutrition.

INFLAMMATORY BOWEL DISEASES (2022)

Article Gastroenterology & Hepatology

Safety and Potential Efficacy of Escalating Dose of Ustekinumab in Pediatric Crohn Disease (the Speed-up Study): A Multicenter Study from the Pediatric IBD Porto Group of ESPGHAN

Anat Yerushalmy-Feler, Gemma Pujol-Muncunill, Javier Martin-de-Carpi, Kaija-Leena Kolho, Arie Levine, Christine Olbjorn, Maya Granot, Matteo Bramuzzo, Helena Rolandsdotter, Natalia Mouratidou, Ondrej Hradsky, Luca Scarallo, Manar Matar, Ramit Magen Rimon, Firas Rinawi, Tzippi Shalem, Hisham Najajra, Tim de Meij, Marina Aloi, Marta Velasco Rodriguez-Belvis, Patrizia Alvisi, Anna-Maria Schneider, Patrick van Rheenen, Victor Manuel Navas-Lopez, Fevronia Kiparissi, Josefa Barrio, Dan Turner, Shlomi Cohen

Summary: Dose escalation of UST is effective in children with Crohn disease, and milder disease activity may predict a favorable outcome following UST dose escalation.

JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2022)

Article Gastroenterology & Hepatology

Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study

Ohad Atia, Zivia Shavit-Brunschwig, Diane R. Mould, Ronen Stein, Manar Matar, Marina Aloi, Oren Ledder, Gili Focht, Darja Urlep, Jeffrey Hyams, Efrat Broide, Batia Weiss, Jeremiah Levine, Richard K. Russell, Dan Turner

Summary: This study evaluated the safety, effectiveness, and dosing of vedolizumab in children with inflammatory bowel disease (IBD). The results showed that vedolizumab had good efficacy in inducing remission in children with IBD, especially those with ulcerative colitis. For children weighing less than 30 kg, a dose of 200 mg/m2 or 10 mg/kg at week 14 was recommended. The importance rating for this study is 8 out of 10.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2023)

Article Medicine, Research & Experimental

DNA methylation of the TPMT gene and azathioprine pharmacokinetics in children with very early onset inflammatory bowel disease

Davide Selvestrel, Gabriele Stocco, Marina Aloi, Serena Arrigo, Sabrina Cardile, Erika Cecchin, Mauro Congia, Debora Curci, Simona Gatti, Francesco Graziano, Carl D. Langefeld, Marianna Lucafo, Stefano Martelossi, Massimo Martinelli, Sofia Pagarin, Luca Scarallo, Elisabetta Francesca Stacul, Caterina Strisciuglio, Susan Thompson, Giovanna Zuin, Giuliana Decorti, Matteo Bramuzzo

Summary: This pharmacoepigenetic study aims to evaluate differences in DNA methylation and TPMT activity between patients with very early onset inflammatory bowel disease (VEO-IBD) and adolescents with IBD (aIBD). The study found that the DNA methylation level of cg22736354 in the TPMT gene neighborhood is lower in VEO-IBD patients, and it is associated with TPMT activity and azathioprine concentration.

BIOMEDICINE & PHARMACOTHERAPY (2023)

Review Gastroenterology & Hepatology

Multidisciplinary Perinatal Care in IBD

Lihi Godny, Vaios Svolos, Astrid-Jane Williams, Wladyslawa Czuber-Dochan, Marina Aloi, Ana Ibarra, Dearbhaile O'Hanlon, Gabriele Dragoni, Irit Avni Biron, Marjo Campmans-Kuijpers, Paul Collins, Piotr Eder, Tamar Pfeffer-Gik, Susanna Jaghult, Catherine L. Wall

Summary: This topical review assessed the non-medical management of patients with inflammatory bowel disease (IBD) during the perinatal period. A consensus expert panel developed 19 practice positions covering preconception, pregnancy, lactation, and early-life exposures. The results indicated that patients with IBD have unique nutritional and psychosocial needs, and the early-life environment of infants born to parents with IBD may be associated with the development of IBD in offspring.

JOURNAL OF CROHNS & COLITIS (2023)

Correction Gastroenterology & Hepatology

Occurrence and Clinical Impact of Eosinophilic Esophagitis in a Large Cohort of Children With Inflammatory Bowel Disease (Aug, 10.1093/ibd/izac172

Marina Aloi, Giulia D'Arcangelo, Danilo Rossetti, Simone Bucherini, Enrico Felici, Claudio Romano, Massimo Martinelli, Valeria Dipasquale, Paolo Lionetti, Salvatore Oliva

INFLAMMATORY BOWEL DISEASES (2023)

Meeting Abstract Gastroenterology & Hepatology

OUTCOME OF INDUCTION THERAPY WITH VEDOLIZUMAB IN CHILDREN: RESULTS FROM THE PROSPECTIVE, MULTICENTER, VEDOKIDS STUDY

Zivia Shavit-Brunschwig, Ronen E. Stein, Marina Aloi, Oren Ledder, Gili Focht, Darja Urlep, Jeffrey S. Hyams, Efrat Broide, Batia Weiss, Jeremiah Levine, Dror Shouval, Manar Matar, Amit Assa, Joel R. Rosh, Seamus Hussey, James Markowitz, Anat Yerushalmy-Feler, Erasmo Miele, Ron Shaoul, Richard K. Russell, Dan Turner

GASTROENTEROLOGY (2022)

Meeting Abstract Gastroenterology & Hepatology

PANENTERIC CAPSULE ENDOSCOPY TO CHARACTERIZE CROHN'S DISEASE PHENOTYPES AND PREDICT CLINICAL OUTCOMES IN CHILDREN AND ADULTS

Salvatore Oliva, Silvio Veraldi, Gian Eugenio Tontini, Pinhas Eidler, Luca Elli, Marina Aloi, Patrizia Alvisi, Virginia Lombardo, Nikolas Dussias, Paolo Gionchetti, Carlo Calabrese

GASTROINTESTINAL ENDOSCOPY (2022)

Meeting Abstract Gastroenterology & Hepatology

CLINICAL FEATURES AND OUTCOMES OF PAEDIATRIC PATIENTS WITH ISOLATED COLONIC CROHN'S DISEASE: A MULTICENTRE STUDY FROM THE PAEDIATRIC IBD PORTO GROUP OF ESPGHAN

Tal Berger, Huey Miin Lee, Lavenya Ramasamy Padmanaban, Eytan Wine, Anat Yerushalmy-Feler, Iva Hojsak, Denis Kazeka, Daniela Elena Serban, Dotan Yogev, Oren Ledder, Paolo Lionetti, Luca Scarallo, Marco Gasparetto, Nicholas M. Croft, Erasmo Miele, Annamaria Staiano, Joseph Meredith, Marina Aloi, Patrizia Alvisi, Darja Urlep, Batia Weiss, Mikkel Malham, Manar Matar, Victor Navas-Lopez, Claudio Romano, Valeria Dipasquale, Lorenzo Norsa, Kaija-Leena Kolho, Raanan Shamir, Dror Shouval

GASTROENTEROLOGY (2022)

Meeting Abstract Gastroenterology & Hepatology

TRENDS IN ADMISSIONS, OUTCOMES AND FINANCIAL BURDEN OF C. DIFFICILE INFECTION RELATED HOSPITALIZATIONS AMONG INFLAMMATORY BOWEL DISEASE PATIENTS: A NATIONWIDE ANALYSIS

Muhammad Waqas Tahir, Raseen Tariq, Zoya Tahir, Arsalan Zaheer, Sahil Khanna

GASTROENTEROLOGY (2022)

No Data Available